Patents Assigned to New Hope Research Foundation
  • Patent number: 11723865
    Abstract: Aspects herein relate to systems and methods for delivery of biologic agents to the central nervous system. In various embodiments, a method of administering a therapeutic agent to the central nervous system (CNS) is included. The method can include injecting a therapeutic agent into a first cerebrospinal fluid (CSF) region of the subject. The method can further include establishing fluid communication between a fluid reservoir and a second cerebrospinal fluid (CSF) region of a subject, the fluid having a hydraulic pressure at or above an intracranial pressure. The method can further include infusing a hyperosmotic fluid systemically. Other embodiments, including kits and systems are also included herein.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: August 15, 2023
    Assignee: New Hope Research Foundation, Inc.
    Inventor: John G. Keimel
  • Patent number: 11541005
    Abstract: Aspects herein relate to systems and methods for delivery of biologic agents to the central nervous system. In various embodiments, a method of administering a therapeutic agent to the central nervous system (CNS) is included. The method can include injecting a therapeutic agent into a first cerebrospinal fluid (CSF) region of the subject. The method can further include establishing fluid communication between a fluid reservoir and a second cerebrospinal fluid (CSF) region of a subject, the fluid having a hydraulic pressure at or above an intracranial pressure. The method can further include infusing a hyperosmotic fluid systemically. Other embodiments, including kits and systems are also included herein.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: January 3, 2023
    Assignee: New Hope Research Foundation, Inc.
    Inventor: John G. Keimel
  • Patent number: 10016514
    Abstract: Embodiments herein include polynucleotides, vectors and methods for the insertion and expression of transgenes. In an embodiment, a polynucleotide is included. The polynucleotide can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. In an embodiment, a recombinant vector is included. The recombinant vector can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. Other embodiments are also included herein.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: July 10, 2018
    Assignee: New Hope Research Foundation
    Inventors: John G. Keimel, Michael David Kaytor